Park Circle Company’s Arcus Biosciences RCUS Stock Holding History

Park Circle Company’s Portfolio RCUS Stock Details RCUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-64,000	Closed	-$1.62M	–	137
2022 Q2	$1.62M	Buy	+64,000	New	+$1.57M	1.33%	20

Other funds holding RCUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

IFA

Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Park Circle Company's RCUS Position: Q4 2023 in Review

Park Circle Company sold out of Arcus Biosciences (RCUS) in Q4 2023, closing a stake of 3,900 shares — an estimated $70K sold.

Park Circle Company first reported a position in RCUS in Q2 2021 and held it in 10 quarters. The position peaked at $2.75M in Q2 2021. 185 funds tracked by Wall St. Rank hold RCUS as of Q4 2023.

Park Circle Company reported no remaining Arcus Biosciences position as of Q4 2023 after selling out during the quarter.
Park Circle Company sold 3,900 Arcus Biosciences shares in Q4 2023, an estimated $70K.
Park Circle Company first reported a position in Arcus Biosciences in Q2 2021 and held it in 10 quarters.
Park Circle Company's Arcus Biosciences position peaked at $2.75M in Q2 2021.
185 funds tracked by Wall St. Rank held Arcus Biosciences as of Q4 2023.

Based on Park Circle Company's 13F filing for Q4 2023, filed 15 Feb 2024.